Search

Your search keyword '"Lee, Y. Y."' showing total 44 results
Start Over Author "Lee, Y. Y." Publisher elsevier b.v.
44 results on '"Lee, Y. Y."'

3. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1

Author

Galles, N, Liu, P, Updike, R, Fullman, N, Nguyen, J, Rolfe, S, Sbarra, A, Schipp, M, Marks, A, Abady, G, Abbas, K, Abbasi, S, Abbastabar, H, Abd-Allah, F, Abdoli, A, Abolhassani, H, Abosetugn, A, Adabi, M, Adamu, A, Adetokunboh, O, Adnani, Q, Advani, S, Afzal, S, Aghamir, S, Ahinkorah, B, Ahmad, S, Ahmad, T, Ahmadi, S, Ahmed, H, Ahmed, M, Ahmed Rashid, T, Ahmed Salih, Y, Akalu, Y, Aklilu, A, Akunna, C, Al Hamad, H, Alahdab, F, Albano, L, Alemayehu, Y, Alene, K, Al-Eyadhy, A, Alhassan, R, Ali, L, Aljunid, S, Almustanyir, S, Altirkawi, K, Alvis-Guzman, N, Amu, H, Andrei, C, Andrei, T, Ansar, A, Ansari-Moghaddam, A, Antonazzo, I, Antony, B, Arabloo, J, Arab-Zozani, M, Artanti, K, Arulappan, J, Awan, A, Awoke, M, Ayza, M, Azarian, G, Azzam, A, B, D, Babar, Z, Balakrishnan, S, Banach, M, Bante, S, Barnighausen, T, Barqawi, H, Barrow, A, Bassat, Q, Bayarmagnai, N, Bejarano Ramirez, D, Bekuma, T, Belay, H, Belgaumi, U, Bhagavathula, A, Bhandari, D, Bhardwaj, N, Bhardwaj, P, Bhaskar, S, Bhattacharyya, K, Bibi, S, Bijani, A, Biondi, A, Boloor, A, Braithwaite, D, Buonsenso, D, Butt, Z, Camargos, P, Carreras, G, Carvalho, F, Castaneda-Orjuela, C, Chakinala, R, Charan, J, Chatterjee, S, Chattu, S, Chattu, V, Chowdhury, F, Christopher, D, Chu, D, Chung, S, Cortesi, P, Costa, V, Couto, R, Dadras, O, Dagnew, A, Dagnew, B, Dai, X, Dandona, L, Dandona, R, De Neve, J, Derbew Molla, M, Derseh, B, Desai, R, Desta, A, Dhamnetiya, D, Dhimal, M, Dianatinasab, M, Diaz, D, Djalalinia, S, Dorostkar, F, Edem, B, Edinur, H, Eftekharzadeh, S, El Sayed, I, El Sayed Zaki, M, Elhadi, M, El-Jaafary, S, Elsharkawy, A, Enany, S, Erkhembayar, R, Esezobor, C, Eskandarieh, S, Ezeonwumelu, I, Ezzikouri, S, Fares, J, Faris, P, Feleke, B, Ferede, T, Fernandes, E, Fernandes, J, Ferrara, P, Filip, I, Fischer, F, Francis, M, Fukumoto, T, Gad, M, Gaidhane, S, Gallus, S, Garg, T, Geberemariyam, B, Gebre, T, Gebregiorgis, B, Gebremedhin, K, Gebremichael, B, Gessner, B, Ghadiri, K, Ghafourifard, M, Ghashghaee, A, Gilani, S, Glavan, I, Glushkova, E, Golechha, M, Gonfa, K, Gopalani, S, Goudarzi, H, Gubari, M, Guo, Y, Gupta, V, Gutierrez, R, Haeuser, E, Halwani, R, Hamidi, S, Hanif, A, Haque, S, Harapan, H, Hargono, A, Hashi, A, Hassan, S, Hassanein, M, Hassanipour, S, Hassankhani, H, Hay, S, Hayat, K, Hegazy, M, Heidari, G, Hezam, K, Holla, R, Hoque, M, Hosseini, M, Hosseinzadeh, M, Hostiuc, M, Househ, M, Hsieh, V, Huang, J, Humayun, A, Hussain, R, Hussein, N, Ibitoye, S, Ilesanmi, O, Ilic, I, Ilic, M, Inamdar, S, Iqbal, U, Irham, L, Irvani, S, Islam, S, Ismail, N, Itumalla, R, Jha, R, Joukar, F, Kabir, A, Kabir, Z, Kalhor, R, Kamal, Z, Kamande, S, Kandel, H, Karch, A, Kassahun, G, Kassebaum, N, Katoto, P, Kelkay, B, Kengne, A, Khader, Y, Khajuria, H, Khalil, I, Khan, E, Khan, G, Khan, J, Khan, M, Khang, Y, Khoja, A, Khubchandani, J, Kim, G, Kim, M, Kim, Y, Kimokoti, R, Kisa, A, Kisa, S, Korshunov, V, Kosen, S, Kuate Defo, B, Kulkarni, V, Kumar, A, Kumar, G, Kumar, N, Kwarteng, A, La Vecchia, C, Lami, F, Landires, I, Lasrado, S, Lassi, Z, Lee, H, Lee, Y, Levi, M, Lewycka, S, Li, S, Liu, X, Lobo, S, Lopukhov, P, Lozano, R, Lutzky Saute, R, Magdy Abd El Razek, M, Makki, A, Malik, A, Mansour-Ghanaei, F, Mansournia, M, Mantovani, L, Martins-Melo, F, Matthews, P, Medina, J, Mendoza, W, Menezes, R, Mengesha, E, Meretoja, T, Mersha, A, Mesregah, M, Mestrovic, T, Miazgowski, B, Milne, G, Mirica, A, Mirrakhimov, E, Mirzaei, H, Misra, S, Mithra, P, Moghadaszadeh, M, Mohamed, T, Mohammad, K, Mohammad, Y, Mohammadi, M, Mohammadian-Hafshejani, A, Mohammed, A, Mohammed, S, Mohapatra, A, Mokdad, A, Molokhia, M, Monasta, L, Moni, M, Montasir, A, Moore, C, Moradi, G, Moradzadeh, R, Moraga, P, Mueller, U, Munro, S, Naghavi, M, Naimzada, M, Naveed, M, Nayak, B, Negoi, I, Neupane Kandel, S, Nguyen, T, Nikbakhsh, R, Ningrum, D, Nixon, M, Nnaji, C, Noubiap, J, Nunez-Samudio, V, Nwatah, V, Oancea, B, Ochir, C, Ogbo, F, Olagunju, A, Olakunde, B, Onwujekwe, O, Otstavnov, N, Otstavnov, S, Owolabi, M, Padubidri, J, Pakshir, K, Park, E, Pashazadeh Kan, F, Pathak, M, Paudel, R, Pawar, S, Pereira, J, Peres, M, Perianayagam, A, Pinheiro, M, Pirestani, M, Podder, V, Polibin, R, Pollok, R, Postma, M, Pottoo, F, Rabiee, M, Rabiee, N, Radfar, A, Rafiei, A, Rahimi-Movaghar, V, Rahman, M, Rahmani, A, Rahmawaty, S, Rajesh, A, Ramshaw, R, Ranasinghe, P, Rao, C, Rao, S, Rathi, P, Rawaf, D, Rawaf, S, Renzaho, A, Rezaei, N, Rezai, M, Rios-Blancas, M, Rogowski, E, Ronfani, L, Rwegerera, G, Saad, A, Sabour, S, Saddik, B, Saeb, M, Saeed, U, Sahebkar, A, Sahraian, M, Salam, N, Salimzadeh, H, Samaei, M, Samy, A, Sanabria, J, Sanmarchi, F, Santric-Milicevic, M, Sartorius, B, Sarveazad, A, Sathian, B, Sawhney, M, Saxena, D, Saxena, S, Seidu, A, Seylani, A, Shaikh, M, Shamsizadeh, M, Shetty, P, Shigematsu, M, Shin, J, Sidemo, N, Singh, A, Singh, J, Sinha, S, Skryabin, V, Skryabina, A, Soheili, A, Tadesse, E, Tamiru, A, Tan, K, Tekalegn, Y, Temsah, M, Thakur, B, Thapar, R, Thavamani, A, Tobe-Gai, R, Tohidinik, H, Tovani-Palone, M, Traini, E, Tran, B, Tripathi, M, Tsegaye, B, Tsegaye, G, Ullah, A, Ullah, S, Unim, B, Vacante, M, Velazquez, D, Vo, B, Vollmer, S, Vu, G, Vu, L, Waheed, Y, Winkler, A, Wiysonge, C, Yigit, V, Yirdaw, B, Yon, D, Yonemoto, N, Yu, C, Yuce, D, Yunusa, I, Zamani, M, Zamanian, M, Zewdie, D, Zhang, Z, Zhong, C, Zumla, A, Murray, C, Lim, S, Mosser, J, Singh Mtech, A, Hargono Dr, A, Galles N. C., Liu P. Y., Updike R. L., Fullman N., Nguyen J., Rolfe S., Sbarra A. N., Schipp M. F., Marks A., Abady G. G., Abbas K. M., Abbasi S. W., Abbastabar H., Abd-Allah F., Abdoli A., Abolhassani H., Abosetugn A. E., Adabi M., Adamu A. A., Adetokunboh O. O., Adnani Q. E. S., Advani S. M., Afzal S., Aghamir S. M. K., Ahinkorah B. O., Ahmad S., Ahmad T., Ahmadi S., Ahmed H., Ahmed M. B., Ahmed Rashid T., Ahmed Salih Y., Akalu Y., Aklilu A., Akunna C. J., Al Hamad H., Alahdab F., Albano L., Alemayehu Y., Alene K. A., Al-Eyadhy A., Alhassan R. K., Ali L., Aljunid S. M., Almustanyir S., Altirkawi K. A., Alvis-Guzman N., Amu H., Andrei C. L., Andrei T., Ansar A., Ansari-Moghaddam A., Antonazzo I. C., Antony B., Arabloo J., Arab-Zozani M., Artanti K. D., Arulappan J., Awan A. T., Awoke M. A., Ayza M. A., Azarian G., Azzam A. Y., B D. B., Babar Z. -U. -D., Balakrishnan S., Banach M., Bante S. A., Barnighausen T. W., Barqawi H. J., Barrow A., Bassat Q., Bayarmagnai N., Bejarano Ramirez D. F., Bekuma T. T., Belay H. G., Belgaumi U. I., Bhagavathula A. S., Bhandari D., Bhardwaj N., Bhardwaj P., Bhaskar S., Bhattacharyya K., Bibi S., Bijani A., Biondi A., Boloor A., Braithwaite D., Buonsenso D., Butt Z. A., Camargos P., Carreras G., Carvalho F., Castaneda-Orjuela C. A., Chakinala R. C., Charan J., Chatterjee S., Chattu S. K., Chattu V. K., Chowdhury F. R., Christopher D. J., Chu D. -T., Chung S. -C., Cortesi P. A., Costa V. M., Couto R. A. S., Dadras O., Dagnew A. B., Dagnew B., Dai X., Dandona L., Dandona R., De Neve J. -W., Derbew Molla M., Derseh B. T., Desai R., Desta A. A., Dhamnetiya D., Dhimal M. L., Dhimal M., Dianatinasab M., Diaz D., Djalalinia S., Dorostkar F., Edem B., Edinur H. A., Eftekharzadeh S., El Sayed I., El Sayed Zaki M., Elhadi M., El-Jaafary S. I., Elsharkawy A., Enany S., Erkhembayar R., Esezobor C. I., Eskandarieh S., Ezeonwumelu I. J., Ezzikouri S., Fares J., Faris P. S., Feleke B. E., Ferede T. Y., Fernandes E., Fernandes J. C., Ferrara P., Filip I., Fischer F., Francis M. R., Fukumoto T., Gad M. M., Gaidhane S., Gallus S., Garg T., Geberemariyam B. S., Gebre T., Gebregiorgis B. G., Gebremedhin K. B., Gebremichael B., Gessner B. D., Ghadiri K., Ghafourifard M., Ghashghaee A., Gilani S. A., Glavan I. -R., Glushkova E. V., Golechha M., Gonfa K. B., Gopalani S. V., Goudarzi H., Gubari M. I. M., Guo Y., Gupta V. B., Gupta V. K., Gutierrez R. A., Haeuser E., Halwani R., Hamidi S., Hanif A., Haque S., Harapan H., Hargono A., Hashi A., Hassan S., Hassanein M. H., Hassanipour S., Hassankhani H., Hay S. I., Hayat K., Hegazy M. I., Heidari G., Hezam K., Holla R., Hoque M. E., Hosseini M., Hosseinzadeh M., Hostiuc M., Househ M., Hsieh V. C. -R., Huang J., Humayun A., Hussain R., Hussein N. R., Ibitoye S. E., Ilesanmi O. S., Ilic I. M., Ilic M. D., Inamdar S., Iqbal U., Irham L. M., Irvani S. S. N., Islam S. M. S., Ismail N. E., Itumalla R., Jha R. P., Joukar F., Kabir A., Kabir Z., Kalhor R., Kamal Z., Kamande S. M., Kandel H., Karch A., Kassahun G., Kassebaum N. J., Katoto P. D., Kelkay B., Kengne A. P., Khader Y. S., Khajuria H., Khalil I. A., Khan E. A., Khan G., Khan J., Khan M., Khan M. A., Khang Y. -H., Khoja A. T., Khubchandani J., Kim G. R., Kim M. S., Kim Y. J., Kimokoti R. W., Kisa A., Kisa S., Korshunov V. A., Kosen S., Kuate Defo B., Kulkarni V., Kumar A., Kumar G. A., Kumar N., Kwarteng A., La Vecchia C., Lami F. H., Landires I., Lasrado S., Lassi Z. S., Lee H., Lee Y. Y., Levi M., Lewycka S., Li S., Liu X., Lobo S. W., Lopukhov P. D., Lozano R., Lutzky Saute R., Magdy Abd El Razek M., Makki A., Malik A. A., Mansour-Ghanaei F., Mansournia M. A., Mantovani L. G., Martins-Melo F. R., Matthews P. C., Medina J. R. C., Mendoza W., Menezes R. G., Mengesha E. W., Meretoja T. J., Mersha A. G., Mesregah M. K., Mestrovic T., Miazgowski B., Milne G. J., Mirica A., Mirrakhimov E. M., Mirzaei H. R., Misra S., Mithra P., Moghadaszadeh M., Mohamed T. A., Mohammad K. A., Mohammad Y., Mohammadi M., Mohammadian-Hafshejani A., Mohammed A., Mohammed S., Mohapatra A., Mokdad A. H., Molokhia M., Monasta L., Moni M. A., Montasir A. A., Moore C. E., Moradi G., Moradzadeh R., Moraga P., Mueller U. O., Munro S. B., Naghavi M., Naimzada M. D., Naveed M., Nayak B. P., Negoi I., Neupane Kandel S., Nguyen T. H., Nikbakhsh R., Ningrum D. N. A., Nixon M. R., Nnaji C. A., Noubiap J. J., Nunez-Samudio V., Nwatah V. E., Oancea B., Ochir C., Ogbo F. A., Olagunju A. T., Olakunde B. O., Onwujekwe O. E., Otstavnov N., Otstavnov S. S., Owolabi M. O., Padubidri J. R., Pakshir K., Park E. -C., Pashazadeh Kan F., Pathak M., Paudel R., Pawar S., Pereira J., Peres M. F. P., Perianayagam A., Pinheiro M., Pirestani M., Podder V., Polibin R. V., Pollok R. C. G., Postma M. J., Pottoo F. H., Rabiee M., Rabiee N., Radfar A., Rafiei A., Rahimi-Movaghar V., Rahman M., Rahmani A. M., Rahmawaty S., Rajesh A., Ramshaw R. E., Ranasinghe P., Rao C. R., Rao S. J., Rathi P., Rawaf D. L., Rawaf S., Renzaho A. M. N., Rezaei N., Rezai M. S., Rios-Blancas M., Rogowski E. L. B., Ronfani L., Rwegerera G. M., Saad A. M., Sabour S., Saddik B., Saeb M. R., Saeed U., Sahebkar A., Sahraian M. A., Salam N., Salimzadeh H., Samaei M., Samy A. M., Sanabria J., Sanmarchi F., Santric-Milicevic M. M., Sartorius B., Sarveazad A., Sathian B., Sawhney M., Saxena D., Saxena S., Seidu A. -A., Seylani A., Shaikh M. A., Shamsizadeh M., Shetty P. H., Shigematsu M., Shin J. I., Sidemo N. B., Singh A., Singh J. A., Sinha S., Skryabin V. Y., Skryabina A. A., Soheili A., Tadesse E. G., Tamiru A. T., Tan K. -K., Tekalegn Y., Temsah M. -H., Thakur B., Thapar R., Thavamani A., Tobe-Gai R., Tohidinik H. R., Tovani-Palone M. R., Traini E., Tran B. X., Tripathi M., Tsegaye B., Tsegaye G. W., Ullah A., Ullah S., Unim B., Vacante M., Velazquez D. Z., Vo B., Vollmer S., Vu G. T., Vu L. G., Waheed Y., Winkler A. S., Wiysonge C. S., Yigit V., Yirdaw B. W., Yon D. K., Yonemoto N., Yu C., Yuce D., Yunusa I., Zamani M., Zamanian M., Zewdie D. T., Zhang Z. -J., Zhong C., Zumla A., Murray C. J. L., Lim S. S., Mosser J. F., Aghamir S., Sahraian M., Mansournia M., Mirzaei H., Temsah M., Andrei C., Glavan I., Antonazzo I., Singh Mtech A., Padubidri J., Babar Z., De Neve J., Noubiap J., Chakinala R., Chattu S., Chattu V., Chu D., Chung S., Kumar G., Gilani S., Gupta V., Hargono Dr A., Islam S., Hsieh V., Irvani S. N., Ismail N., Khang Y., Yon D., Kim G., Park E., Shin J., Kim M., Kim Y., Lee Y., Medina J. C., Naimzada M., Rahmani A., Rezai M., Rao S., Saeb M., Seidu A., Tan K., Tohidinik H., Zhang Z., Galles, N, Liu, P, Updike, R, Fullman, N, Nguyen, J, Rolfe, S, Sbarra, A, Schipp, M, Marks, A, Abady, G, Abbas, K, Abbasi, S, Abbastabar, H, Abd-Allah, F, Abdoli, A, Abolhassani, H, Abosetugn, A, Adabi, M, Adamu, A, Adetokunboh, O, Adnani, Q, Advani, S, Afzal, S, Aghamir, S, Ahinkorah, B, Ahmad, S, Ahmad, T, Ahmadi, S, Ahmed, H, Ahmed, M, Ahmed Rashid, T, Ahmed Salih, Y, Akalu, Y, Aklilu, A, Akunna, C, Al Hamad, H, Alahdab, F, Albano, L, Alemayehu, Y, Alene, K, Al-Eyadhy, A, Alhassan, R, Ali, L, Aljunid, S, Almustanyir, S, Altirkawi, K, Alvis-Guzman, N, Amu, H, Andrei, C, Andrei, T, Ansar, A, Ansari-Moghaddam, A, Antonazzo, I, Antony, B, Arabloo, J, Arab-Zozani, M, Artanti, K, Arulappan, J, Awan, A, Awoke, M, Ayza, M, Azarian, G, Azzam, A, B, D, Babar, Z, Balakrishnan, S, Banach, M, Bante, S, Barnighausen, T, Barqawi, H, Barrow, A, Bassat, Q, Bayarmagnai, N, Bejarano Ramirez, D, Bekuma, T, Belay, H, Belgaumi, U, Bhagavathula, A, Bhandari, D, Bhardwaj, N, Bhardwaj, P, Bhaskar, S, Bhattacharyya, K, Bibi, S, Bijani, A, Biondi, A, Boloor, A, Braithwaite, D, Buonsenso, D, Butt, Z, Camargos, P, Carreras, G, Carvalho, F, Castaneda-Orjuela, C, Chakinala, R, Charan, J, Chatterjee, S, Chattu, S, Chattu, V, Chowdhury, F, Christopher, D, Chu, D, Chung, S, Cortesi, P, Costa, V, Couto, R, Dadras, O, Dagnew, A, Dagnew, B, Dai, X, Dandona, L, Dandona, R, De Neve, J, Derbew Molla, M, Derseh, B, Desai, R, Desta, A, Dhamnetiya, D, Dhimal, M, Dianatinasab, M, Diaz, D, Djalalinia, S, Dorostkar, F, Edem, B, Edinur, H, Eftekharzadeh, S, El Sayed, I, El Sayed Zaki, M, Elhadi, M, El-Jaafary, S, Elsharkawy, A, Enany, S, Erkhembayar, R, Esezobor, C, Eskandarieh, S, Ezeonwumelu, I, Ezzikouri, S, Fares, J, Faris, P, Feleke, B, Ferede, T, Fernandes, E, Fernandes, J, Ferrara, P, Filip, I, Fischer, F, Francis, M, Fukumoto, T, Gad, M, Gaidhane, S, Gallus, S, Garg, T, Geberemariyam, B, Gebre, T, Gebregiorgis, B, Gebremedhin, K, Gebremichael, B, Gessner, B, Ghadiri, K, Ghafourifard, M, Ghashghaee, A, Gilani, S, Glavan, I, Glushkova, E, Golechha, M, Gonfa, K, Gopalani, S, Goudarzi, H, Gubari, M, Guo, Y, Gupta, V, Gutierrez, R, Haeuser, E, Halwani, R, Hamidi, S, Hanif, A, Haque, S, Harapan, H, Hargono, A, Hashi, A, Hassan, S, Hassanein, M, Hassanipour, S, Hassankhani, H, Hay, S, Hayat, K, Hegazy, M, Heidari, G, Hezam, K, Holla, R, Hoque, M, Hosseini, M, Hosseinzadeh, M, Hostiuc, M, Househ, M, Hsieh, V, Huang, J, Humayun, A, Hussain, R, Hussein, N, Ibitoye, S, Ilesanmi, O, Ilic, I, Ilic, M, Inamdar, S, Iqbal, U, Irham, L, Irvani, S, Islam, S, Ismail, N, Itumalla, R, Jha, R, Joukar, F, Kabir, A, Kabir, Z, Kalhor, R, Kamal, Z, Kamande, S, Kandel, H, Karch, A, Kassahun, G, Kassebaum, N, Katoto, P, Kelkay, B, Kengne, A, Khader, Y, Khajuria, H, Khalil, I, Khan, E, Khan, G, Khan, J, Khan, M, Khang, Y, Khoja, A, Khubchandani, J, Kim, G, Kim, M, Kim, Y, Kimokoti, R, Kisa, A, Kisa, S, Korshunov, V, Kosen, S, Kuate Defo, B, Kulkarni, V, Kumar, A, Kumar, G, Kumar, N, Kwarteng, A, La Vecchia, C, Lami, F, Landires, I, Lasrado, S, Lassi, Z, Lee, H, Lee, Y, Levi, M, Lewycka, S, Li, S, Liu, X, Lobo, S, Lopukhov, P, Lozano, R, Lutzky Saute, R, Magdy Abd El Razek, M, Makki, A, Malik, A, Mansour-Ghanaei, F, Mansournia, M, Mantovani, L, Martins-Melo, F, Matthews, P, Medina, J, Mendoza, W, Menezes, R, Mengesha, E, Meretoja, T, Mersha, A, Mesregah, M, Mestrovic, T, Miazgowski, B, Milne, G, Mirica, A, Mirrakhimov, E, Mirzaei, H, Misra, S, Mithra, P, Moghadaszadeh, M, Mohamed, T, Mohammad, K, Mohammad, Y, Mohammadi, M, Mohammadian-Hafshejani, A, Mohammed, A, Mohammed, S, Mohapatra, A, Mokdad, A, Molokhia, M, Monasta, L, Moni, M, Montasir, A, Moore, C, Moradi, G, Moradzadeh, R, Moraga, P, Mueller, U, Munro, S, Naghavi, M, Naimzada, M, Naveed, M, Nayak, B, Negoi, I, Neupane Kandel, S, Nguyen, T, Nikbakhsh, R, Ningrum, D, Nixon, M, Nnaji, C, Noubiap, J, Nunez-Samudio, V, Nwatah, V, Oancea, B, Ochir, C, Ogbo, F, Olagunju, A, Olakunde, B, Onwujekwe, O, Otstavnov, N, Otstavnov, S, Owolabi, M, Padubidri, J, Pakshir, K, Park, E, Pashazadeh Kan, F, Pathak, M, Paudel, R, Pawar, S, Pereira, J, Peres, M, Perianayagam, A, Pinheiro, M, Pirestani, M, Podder, V, Polibin, R, Pollok, R, Postma, M, Pottoo, F, Rabiee, M, Rabiee, N, Radfar, A, Rafiei, A, Rahimi-Movaghar, V, Rahman, M, Rahmani, A, Rahmawaty, S, Rajesh, A, Ramshaw, R, Ranasinghe, P, Rao, C, Rao, S, Rathi, P, Rawaf, D, Rawaf, S, Renzaho, A, Rezaei, N, Rezai, M, Rios-Blancas, M, Rogowski, E, Ronfani, L, Rwegerera, G, Saad, A, Sabour, S, Saddik, B, Saeb, M, Saeed, U, Sahebkar, A, Sahraian, M, Salam, N, Salimzadeh, H, Samaei, M, Samy, A, Sanabria, J, Sanmarchi, F, Santric-Milicevic, M, Sartorius, B, Sarveazad, A, Sathian, B, Sawhney, M, Saxena, D, Saxena, S, Seidu, A, Seylani, A, Shaikh, M, Shamsizadeh, M, Shetty, P, Shigematsu, M, Shin, J, Sidemo, N, Singh, A, Singh, J, Sinha, S, Skryabin, V, Skryabina, A, Soheili, A, Tadesse, E, Tamiru, A, Tan, K, Tekalegn, Y, Temsah, M, Thakur, B, Thapar, R, Thavamani, A, Tobe-Gai, R, Tohidinik, H, Tovani-Palone, M, Traini, E, Tran, B, Tripathi, M, Tsegaye, B, Tsegaye, G, Ullah, A, Ullah, S, Unim, B, Vacante, M, Velazquez, D, Vo, B, Vollmer, S, Vu, G, Vu, L, Waheed, Y, Winkler, A, Wiysonge, C, Yigit, V, Yirdaw, B, Yon, D, Yonemoto, N, Yu, C, Yuce, D, Yunusa, I, Zamani, M, Zamanian, M, Zewdie, D, Zhang, Z, Zhong, C, Zumla, A, Murray, C, Lim, S, Mosser, J, Singh Mtech, A, Hargono Dr, A, Galles N. C., Liu P. Y., Updike R. L., Fullman N., Nguyen J., Rolfe S., Sbarra A. N., Schipp M. F., Marks A., Abady G. G., Abbas K. M., Abbasi S. W., Abbastabar H., Abd-Allah F., Abdoli A., Abolhassani H., Abosetugn A. E., Adabi M., Adamu A. A., Adetokunboh O. O., Adnani Q. E. S., Advani S. M., Afzal S., Aghamir S. M. K., Ahinkorah B. O., Ahmad S., Ahmad T., Ahmadi S., Ahmed H., Ahmed M. B., Ahmed Rashid T., Ahmed Salih Y., Akalu Y., Aklilu A., Akunna C. J., Al Hamad H., Alahdab F., Albano L., Alemayehu Y., Alene K. A., Al-Eyadhy A., Alhassan R. K., Ali L., Aljunid S. M., Almustanyir S., Altirkawi K. A., Alvis-Guzman N., Amu H., Andrei C. L., Andrei T., Ansar A., Ansari-Moghaddam A., Antonazzo I. C., Antony B., Arabloo J., Arab-Zozani M., Artanti K. D., Arulappan J., Awan A. T., Awoke M. A., Ayza M. A., Azarian G., Azzam A. Y., B D. B., Babar Z. -U. -D., Balakrishnan S., Banach M., Bante S. A., Barnighausen T. W., Barqawi H. J., Barrow A., Bassat Q., Bayarmagnai N., Bejarano Ramirez D. F., Bekuma T. T., Belay H. G., Belgaumi U. I., Bhagavathula A. S., Bhandari D., Bhardwaj N., Bhardwaj P., Bhaskar S., Bhattacharyya K., Bibi S., Bijani A., Biondi A., Boloor A., Braithwaite D., Buonsenso D., Butt Z. A., Camargos P., Carreras G., Carvalho F., Castaneda-Orjuela C. A., Chakinala R. C., Charan J., Chatterjee S., Chattu S. K., Chattu V. K., Chowdhury F. R., Christopher D. J., Chu D. -T., Chung S. -C., Cortesi P. A., Costa V. M., Couto R. A. S., Dadras O., Dagnew A. B., Dagnew B., Dai X., Dandona L., Dandona R., De Neve J. -W., Derbew Molla M., Derseh B. T., Desai R., Desta A. A., Dhamnetiya D., Dhimal M. L., Dhimal M., Dianatinasab M., Diaz D., Djalalinia S., Dorostkar F., Edem B., Edinur H. A., Eftekharzadeh S., El Sayed I., El Sayed Zaki M., Elhadi M., El-Jaafary S. I., Elsharkawy A., Enany S., Erkhembayar R., Esezobor C. I., Eskandarieh S., Ezeonwumelu I. J., Ezzikouri S., Fares J., Faris P. S., Feleke B. E., Ferede T. Y., Fernandes E., Fernandes J. C., Ferrara P., Filip I., Fischer F., Francis M. R., Fukumoto T., Gad M. M., Gaidhane S., Gallus S., Garg T., Geberemariyam B. S., Gebre T., Gebregiorgis B. G., Gebremedhin K. B., Gebremichael B., Gessner B. D., Ghadiri K., Ghafourifard M., Ghashghaee A., Gilani S. A., Glavan I. -R., Glushkova E. V., Golechha M., Gonfa K. B., Gopalani S. V., Goudarzi H., Gubari M. I. M., Guo Y., Gupta V. B., Gupta V. K., Gutierrez R. A., Haeuser E., Halwani R., Hamidi S., Hanif A., Haque S., Harapan H., Hargono A., Hashi A., Hassan S., Hassanein M. H., Hassanipour S., Hassankhani H., Hay S. I., Hayat K., Hegazy M. I., Heidari G., Hezam K., Holla R., Hoque M. E., Hosseini M., Hosseinzadeh M., Hostiuc M., Househ M., Hsieh V. C. -R., Huang J., Humayun A., Hussain R., Hussein N. R., Ibitoye S. E., Ilesanmi O. S., Ilic I. M., Ilic M. D., Inamdar S., Iqbal U., Irham L. M., Irvani S. S. N., Islam S. M. S., Ismail N. E., Itumalla R., Jha R. P., Joukar F., Kabir A., Kabir Z., Kalhor R., Kamal Z., Kamande S. M., Kandel H., Karch A., Kassahun G., Kassebaum N. J., Katoto P. D., Kelkay B., Kengne A. P., Khader Y. S., Khajuria H., Khalil I. A., Khan E. A., Khan G., Khan J., Khan M., Khan M. A., Khang Y. -H., Khoja A. T., Khubchandani J., Kim G. R., Kim M. S., Kim Y. J., Kimokoti R. W., Kisa A., Kisa S., Korshunov V. A., Kosen S., Kuate Defo B., Kulkarni V., Kumar A., Kumar G. A., Kumar N., Kwarteng A., La Vecchia C., Lami F. H., Landires I., Lasrado S., Lassi Z. S., Lee H., Lee Y. Y., Levi M., Lewycka S., Li S., Liu X., Lobo S. W., Lopukhov P. D., Lozano R., Lutzky Saute R., Magdy Abd El Razek M., Makki A., Malik A. A., Mansour-Ghanaei F., Mansournia M. A., Mantovani L. G., Martins-Melo F. R., Matthews P. C., Medina J. R. C., Mendoza W., Menezes R. G., Mengesha E. W., Meretoja T. J., Mersha A. G., Mesregah M. K., Mestrovic T., Miazgowski B., Milne G. J., Mirica A., Mirrakhimov E. M., Mirzaei H. R., Misra S., Mithra P., Moghadaszadeh M., Mohamed T. A., Mohammad K. A., Mohammad Y., Mohammadi M., Mohammadian-Hafshejani A., Mohammed A., Mohammed S., Mohapatra A., Mokdad A. H., Molokhia M., Monasta L., Moni M. A., Montasir A. A., Moore C. E., Moradi G., Moradzadeh R., Moraga P., Mueller U. O., Munro S. B., Naghavi M., Naimzada M. D., Naveed M., Nayak B. P., Negoi I., Neupane Kandel S., Nguyen T. H., Nikbakhsh R., Ningrum D. N. A., Nixon M. R., Nnaji C. A., Noubiap J. J., Nunez-Samudio V., Nwatah V. E., Oancea B., Ochir C., Ogbo F. A., Olagunju A. T., Olakunde B. O., Onwujekwe O. E., Otstavnov N., Otstavnov S. S., Owolabi M. O., Padubidri J. R., Pakshir K., Park E. -C., Pashazadeh Kan F., Pathak M., Paudel R., Pawar S., Pereira J., Peres M. F. P., Perianayagam A., Pinheiro M., Pirestani M., Podder V., Polibin R. V., Pollok R. C. G., Postma M. J., Pottoo F. H., Rabiee M., Rabiee N., Radfar A., Rafiei A., Rahimi-Movaghar V., Rahman M., Rahmani A. M., Rahmawaty S., Rajesh A., Ramshaw R. E., Ranasinghe P., Rao C. R., Rao S. J., Rathi P., Rawaf D. L., Rawaf S., Renzaho A. M. N., Rezaei N., Rezai M. S., Rios-Blancas M., Rogowski E. L. B., Ronfani L., Rwegerera G. M., Saad A. M., Sabour S., Saddik B., Saeb M. R., Saeed U., Sahebkar A., Sahraian M. A., Salam N., Salimzadeh H., Samaei M., Samy A. M., Sanabria J., Sanmarchi F., Santric-Milicevic M. M., Sartorius B., Sarveazad A., Sathian B., Sawhney M., Saxena D., Saxena S., Seidu A. -A., Seylani A., Shaikh M. A., Shamsizadeh M., Shetty P. H., Shigematsu M., Shin J. I., Sidemo N. B., Singh A., Singh J. A., Sinha S., Skryabin V. Y., Skryabina A. A., Soheili A., Tadesse E. G., Tamiru A. T., Tan K. -K., Tekalegn Y., Temsah M. -H., Thakur B., Thapar R., Thavamani A., Tobe-Gai R., Tohidinik H. R., Tovani-Palone M. R., Traini E., Tran B. X., Tripathi M., Tsegaye B., Tsegaye G. W., Ullah A., Ullah S., Unim B., Vacante M., Velazquez D. Z., Vo B., Vollmer S., Vu G. T., Vu L. G., Waheed Y., Winkler A. S., Wiysonge C. S., Yigit V., Yirdaw B. W., Yon D. K., Yonemoto N., Yu C., Yuce D., Yunusa I., Zamani M., Zamanian M., Zewdie D. T., Zhang Z. -J., Zhong C., Zumla A., Murray C. J. L., Lim S. S., Mosser J. F., Aghamir S., Sahraian M., Mansournia M., Mirzaei H., Temsah M., Andrei C., Glavan I., Antonazzo I., Singh Mtech A., Padubidri J., Babar Z., De Neve J., Noubiap J., Chakinala R., Chattu S., Chattu V., Chu D., Chung S., Kumar G., Gilani S., Gupta V., Hargono Dr A., Islam S., Hsieh V., Irvani S. N., Ismail N., Khang Y., Yon D., Kim G., Park E., Shin J., Kim M., Kim Y., Lee Y., Medina J. C., Naimzada M., Rahmani A., Rezai M., Rao S., Saeb M., Seidu A., Tan K., Tohidinik H., and Zhang Z.

Abstract

Background: Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time. Methods: For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development. Findings: By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019

Published
2021

7. Urbanization and prevalence of depression in diabetes.

Author

Lin, C. H., Lee, Y. Y., Liu, C. C., Chen, H. F., Ko, M. C., and Li, C. Y.

Subjects
*MEDICAL research, *URBAN health, *DISEASE prevalence, *MENTAL depression, *DIABETES, *SECULAR changes (Child development)
Abstract

Objectives: To depict recent secular trend (2001-2005) in prevalence of depression among diabetic population in Taiwan, and to explore the influences of urbanization on the prevalence of depression. Study design: A descriptive correlation study design relating urbanization and prevalence of depression. Methods: Annual prevalence of depression was calculated as the ratio of number of individuals with depression (ICD-9-CM: 296, 309, or 311) to the size of diabetic population (ICD-9-CM: 250), which were ascertained from ambulatory care claim data of Taiwan's National Health Insurance between 2001 and 2005. Multivariate Poisson regression analysis was used to assess the secular trend in the prevalence of comorbid depression, and to appraise the influence of urbanization on prevalence of depression in diabetic patients. Results: The prevalence of depression among diabetic population increased annually from 22.6/10³ in 2001 to 27.0/10³ in 2005 with a significantly and linearly rising trend (β = 0.0461, p < 0.0001). Diabetic population living in urban areas showed the largest increase in prevalence (6.3/10³), followed by those from rural areas (5.6/10³). Compared to the diabetic patients residing in rural areas, those living in urban areas (RR = 1.28, 95% CI = 1.25--1.31) and those from satellite towns (RR = 1.22, 95% CI = 1.19-1.25) both had significantly increased adjusted RR. Conclusions: There is a significant increasing trend in prevalence of depression among diabetic population in recent years in Taiwan. Diabetic patients from urban areas not only had the greatest prevalence of depression but also showed the largest increase in prevalence during the study period, which highlights a need for managing depression in urban diabetes. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

8. β-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma.

Author

Jeon, S.-Y., Kwon, S.-H., Seong, Y.-H., Bae, K., Hur, J.-M., Lee, Y.-Y., Suh, D.-Y., and Song, K.-S.

Abstract

Abstract: In the course of searching for BACE1 (β-secretase) inhibitors from natural products, the ethyl acetate soluble fraction of Smilax Rhizoma (the dried rhizomes of Smilax china L.) showed potent inhibitory activity. The active compounds were identified as a trans/cis-resveratrol mixture, oxyresveratrol, veraphenol, and cis-scirpusin A. They were shown to non-competitively inhibit BACE1 with the Ki values of 5.4×10−6, 5.4×10−6, 3.4×10−6, and 5.4×10−6 M and IC50 values of 1.5×10−5, 7.6×10−6, 4.2×10−6, and 1.0×10−5 M, respectively. The active compounds were less inhibitory to α-secretase (TACE) and other serine proteases such as chymotrypsin, trypsin, and elastase, suggesting that they were relatively specific inhibitors of BACE1. [Copyright &y& Elsevier]

Published
2007
Full Text
View/download PDF

9. Dexmedetomidine infusion as a supplement to isoflurane anaesthesia for vitreoretinal surgery.

Author

Lee, Y Y S, Wong, S M, and Hung, C T

Abstract

Background: We explored the sympatholytic property of dexmedetomidine, especially its role in intraocular pressure (IOP) reduction, haemodynamic stability, and attenuation of extubation response.Method: In this double-blind, randomized, controlled trial approved by the Hospital Ethics Committee, 60 patients undergoing elective vitreoretinal surgery were allocated to two groups, receiving either placebo or dexmedetomidine. A loading dose of dexmedetomidine 2.5 microg kg(-1) h(-1) (or placebo in same volume) was infused for 10 min immediately before induction of anaesthesia with propofol, followed by a maintenance dexmedetomidine or placebo infusion at 0.4 microg kg(-1) h(-1) till 30 min before the end of the operation. Anaesthesia was maintained with isoflurane, oxygen, and air mixture. IOP was measured before the loading dose and 1 min after tracheal intubation. The mean arterial pressure (MAP) and heart rate (HR) during loading, induction, maintenance, extubation, and recovery period were measured. The degree of strain on extubation was graded from 0 to 5.Results: The use of vasopressor/labetalol/atropine and the reduction in IOP were comparable between the two groups. There was a significant variation in MAP and HR over time within group, but not between groups. The median degree of strain was significantly lower (P = 0.049), and the time to reach Aldrete score of 10 shorter (P = 0.031) in the dexmedetomidine group.Conclusion: Dexmedetomidine can be used without undue haemodynamic fluctuation and can decrease the excitatory response during extubation. The reduction in IOP with dexmedetomidine was comparable with placebo. [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

10. Determination of porosity of thin protective films on iron base materials and modelling of their development during aqueous corrosion

Author

Lee, Y.-Y., Enders, B., and Ensinger, W.

Subjects
*POROSITY, *THIN films, *CARBON, *ELECTROCHEMICAL analysis
Abstract

Corrosion properties of thin protective films on corroding substrates are dependent on the electrochemical properties of the substrate materials, the intrinsic corrosion properties of thin protective films and also on the films porosity. Therefore knowledge about the porosity is required in order to be able to control and optimise the deposition process. In this contribution a recently developed method to measure the porosity by means of an electrochemical technique is applied. As a model system thin iron films were deposited on silicon wafers and coated with amorphous carbon as a protective layer. The depositions were done by vacuum evaporation and ion assisted sputter deposition. Raman measurements, scanning electron microscopy, atomic force microscopy and electrochemical polarisation measurements were carried out to characterize the films. A model based on geometrical considerations is used to describe the development of the pores during corrosion. The measurement results show that the model is able to extract data on the pores. [Copyright &y& Elsevier]

Published
2004
Full Text
View/download PDF

11. P0094 CSF2 overexpression as a poor prognostic factor in patients with urothelial carcinoma of the upper urinary tract and urinary bladder.

Author

Lee, Y.-Y., Wu, W.-J., Huang, C.-N., Li, C.-C., Ke, H.-L., Li, W.-M., Yeh, H.-C., Li, C.-F., Lin, H.-H., Yeh, B.-W., Hwang, S.-J., and Liang, P.-I.

Subjects
*ACADEMIC medical centers, *CONFERENCES & conventions, *MULTIVARIATE analysis, *POLYMERASE chain reaction, *TUMOR markers, *REVERSE transcriptase polymerase chain reaction, *PROGNOSIS, BLADDER tumors
Abstract

Background: Through data mining of a published transcriptomic database of urothelial carcinomas of the urinary bladder (GSE32894), colony stimulating factor 2 (CSF2) was identified as the most significant gene showing stepwise upregulation related to positive regulation of tyrosine phosphorylation of STAT5 (GO:0042523). We therefore analysed CSF2 transcript and protein expression and their association with clinicopathological factors and survival in our well-characterised cohort of urothelial carcinomas. Methods: Laser capture microdissection coupled with real-time qRT-PCR was used to detect CSF2 transcript level in 24 urothelial carcinomas of the urinary bladder and six non-tumour urothelium samples. Immunohistochemistry evaluated by using H-score was used to determine CSF2 protein expression in 296 urothelial carcinomas of the urinary bladder and 340 urothelial carcinomas of the upper urinary tract. Protein expression was correlated with clinicopathological features and disease-specific survival (DSS) and metastasis-free survival (MeFS). Findings: CSF2 transcripts were detected exclusively in tumour lesions (p=0.010) with stepwise upregulation. CSF2 protein overexpression was significantly associated with advanced pT status (urothelial carcinomas of the upper urinary tract, p=0.011; urothelial carcinomas of the urinary bladder, p<0.001), and perineural invasion (urothelial carcinomas of the upper urinary tract, p=0.002; urothelial carcinomas of the urinary bladder, p= 0.001) in both groups of urothelial carcinoma. CSF2 overexpression not only predicted worse DSS (urothelial carcinomas of the upper urinary tract, p=0.0001; urothelial carcinomas of the urinary bladder, p<0.0001) and MeFS (urothelial carcinomas of the upper urinary tract, p=0.0001; urothelial carcinomas of the urinary bladder, p=0.0002) at univariate analysis, but also inferior DSS (urothelial carcinomas of the upper urinary tract, p=0.015; urothelial carcinomas of the urinary bladder, p=0.004) and MeFS (urothelial carcinomas of the upper urinary tract, p=0.008; urothelial carcinomas of the urinary bladder, p=0.027) in multivariate analysis. Interpretation: CSF2 overexpression is associated with advanced clinical features for both patients with urothelial carcinomas of the upper urinary tract and urothelial carcinomas of the urinary bladder, suggesting it may serve as a potential prognostic and a novel therapeutic target of urothelial carcinoma. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

16. P210 Cyclin-dependent kinase 4 overexpression confers an independent prognosticator of nasopharyngeal carcinoma.

Author

Chen, T.-J., Lee, Y.-Y., and Li, C.-F.

Subjects
*GENE expression, *MULTIVARIATE analysis, *PHOSPHOTRANSFERASES, *PROBABILITY theory, *DESCRIPTIVE statistics, *PROGNOSIS, NASOPHARYNX tumors
Abstract

Background: Data mining on a public domain demonstrated that cyclin dependent kinase 4 (CDK4) was highly expressed in nasopharyngeal carcinoma (NPC). Associated with cyclin-D, CDK4 phosphorylates and inactivates retinoblastoma (Rb) protein family members and mediates progression through G1 to S-phase in the cell cycle. Overexpression of CDK4 has been identified in oral squamous cell carcinoma, lung and breast cancers, sarcomas, and melanomas. However, the expression of CDK4 has never been reported in NPC. This study investigated the expression status, correlation with clinicopathological features, and prognostic implications of CDK4 in a well-defined cohort of NPC. Methods: We retrospectively assessed CDK4 immunoexpression in biopsies of 124 consecutive NPC patients who did not have initial distant metastasis and who received treatment according to consistent guidelines. The results were correlated with clinicopathological features, local recurrence-free survival (LRFS), distant metastasis-free survival (DMeFS), and disease-specific survival (DSS). Findings: High levels of CDK4 protein were positively correlated with T3,4 status (p=0.024), N2,3 status (p<0.001), and American Joint Committee on Cancer stage III, IV (p<0.001). Multivariate analysis suggested that high CDK4 expression was an independent prognostic indicator for worse DMeFS (p=0.001, hazard ratio [HR] 3.226) and DSS (p=0.037, HR 1.838). Interpretation: CDK4 overexpression represents a potential prognostic biomarker in NPC and may confer tumour aggressiveness through cell cycle dysregulation. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

40. P0119 PTP4A3 overexpression predicts clinical aggressiveness in urothelial carcinoma.

Author

Yeh, H.-C., Wu, W.-J., Huang, C.-N., Li, C.-C., Ke, H.-L., Li, W.-M., Li, C.-F., Lee, Y.-Y., Lin, H.-H., Yeh, B.-W., Hwang, S.-J., and Liang, P.-I.

Subjects
*CANCER patients, *GENE expression, *EVALUATION of medical care, *PROTEINS, *SERIAL publications, *TUMORS, *DISEASE complications, *DIAGNOSIS, GENITOURINARY organ tumors
Abstract

Background: Data mining from a published transcriptome of urinary bladder urothelial carcinomas (GSE32894), PTP4A3 was identified as the most significantly upregulated gene among those related to prenylated protein tyrosine phosphatase activity (GO: 0004727). We therefore analysed PTP4A3 transcript and protein expression and their clinicopathological and prognostic significance in our well-characterised cohort of urothelial carcinomas. Methods: PTP4A3 transcript level was assessed in 23 samples of urothelial carcinoma of the urinary bladder with laser capture microdissection coupled with real-time qRT-PCR. PTP4A3 protein expression was determined by immunohistochemistry and evaluated by using H-score in 296 urinary bladder urothelial carcinomas and 340 upper urinary tract urothelial carcinomas, respectively. Both transcript and protein expression statuses were further correlated with clinicopathological features and protein expression was tested for disease-specific survival (DSS) and metastasis-free survival (MeFS). Findings: PTP4A3 transcripts were markedly upregulated in deeply invasive urothelial carcinomas (p<0.001). For both urinary tract and urinary bladder urothelial carcinomas, PTP4A3 protein overexpression was significantly associated with advanced pT status (both p<0.001), nodal metastasis (both p<0.001), and vascular invasion (both p<0.001). PTP4A3 overexpression not only predicted worse DSS (both p<0.0001) and MeFS (upper urinary tract, p<0.0001; urinary bladder, p=0.0005) at univariate analysis, but also inferior DSS (upper urinary tract, p=0.001; urinary bladder, p<0.001) and MeFS (upper urinary tract, p=0.001; urinary bladder, p=0.007) in multivariate analysis. Interpretation: PTP4A3 overexpression is an independent prognosticator for urothelial carcinoma, suggesting its potential prognostic and therapeutic value in urothelial carcinoma. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

42. P0108 Overexpression of DPP4 is a poor prognostic factor for patients with urothelial carcinoma of the upper urinary tract and urinary bladder.

Author

Liang, P.-I., Wu, W.-J., Huang, C.-N., Li, C.-C., Ke, H.-L., Li, W.-M., Yeh, H.-C., Li, C.-F., Lee, Y.-Y., Lin, H.-H., Yeh, B.-W., and Hwang, S.-J.

Subjects
*BLADDER, *CLINICAL drug trials, *ENZYME inhibitors, *ENZYMES, *GENE expression, *HYPOGLYCEMIC agents, *EVALUATION of medical care, *METASTASIS, *SERIAL publications, *SURVIVAL, *TUMORS, *DIAGNOSIS, *ANATOMY, BLADDER tumors, GENITOURINARY organ tumors
Abstract

Background: Dipeptidyl peptidase-4 (DPP4), also known as CD26, is an enzyme that cleaves a diversity of protein that contains proline or analine, including chemokines, growth factors, and neuropeptide. Different DPP4 expression status has been observed in malignant tumours, including colon, renal, and ovarian carcinoma. Data mining of the published dataset (GSE31684) identified that DPP4 is significantly upregulated in urothelial carcinoma of the urinary bladder. We therefore analysed the association of DPP4 expression and outcome in our well-characterised cohort of urothelial carcinoma. Methods: Laser capture microdissection coupled with real-time qRT-PCR was used to evaluate DPP4 transcript level in 20 urothelial carcinomas of the urinary bladder. DPP4 immunostaining was done on 340 cases of urothelial carcinoma of the upper urinary tract and 295 cases of urothelial carcinoma of the urinary bladder. The expression status of DPP4 was then correlated with various clincopathological factors, disease-specific survival (DSS), and metastasis-free survival (MeFS). Findings: DPP4 mRNA expression was significantly increased in urothelial carcinomas with higher pT status (p<0.001). In both groups of urothelial carcinomas, increment of DPP4 immunoexpression was significantly associated with advanced pT stage (both p<0.001), high histological grade (urothelial carcinoma of the upper urinary tract, p=0.019), lymph node metastasis (urothelial carcinoma of the upper urinary tract, p<0.001; urothelial carcinoma of the urinary bladder, p=0.033), vascular invasion (both p<0.001), perineurial invasion (urothelial carcinoma of the urinary bladder, p=0.021) and frequent mitosis (urothelial carcinoma of the upper urinary tract, p=0.003). DPP4 overexpression independently predicted poor DSS (urothelial carcinoma of the upper urinary tract, p=0.028; urothelial carcinoma of the urinary bladder, p<0.0001) and MeFS (urothelial carcinoma of the upper urinary tract, p=0.031; urothelial carcinoma of the urinary bladder, p<0.0001) in both groups of patients. Interpretation: Our study shows that overexpression of DPP4 is significantly associated with aggressive tumour behaviour and poor outcome. DPP4 may have an important role in tumorigenesis of urothelial carcinoma. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

43. P0120 MMP11 overexpression: Poor prognosis in patients with urothelial carcinoma of the upper tract and urinary bladder.

Author

Li, W.-M., Wu, W.-J., Huang, C.-N., Li, C.-C., Ke, H.-L., Yeh, H.-C., Li, C.-F., Lee, Y.-Y., Lin, H.-H., Yeh, B.-W., Hwang, S.-J., and Liang, P.-I.

Subjects
*GENE expression, *GENES, *EVALUATION of medical care, *SERIAL publications, *TUMORS, *URINARY organ physiology, *DIAGNOSIS, BLADDER tumors
Abstract

Background: Through data mining from a published transcriptomic database of urinary bladder urothelial carcinomas (GSE32894), MMP11 was identified as the most significant gene showing stepwise upregulation among those associated with the regulation of metalloendopeptidase activity. We therefore analysed MMP11 protein expression and its association with clinicopathological factors and survival in our well-characterised cohort of urothelial cancers. Methods: Immunohistochemistry evaluated by using H-score was used to determine MMP11 protein expression in 295 urothelial carcinomas of the urinary bladder and 340 urothelial carcinomas of the upper urinary tract, respectively. The medical records of these patients were reviewed retrospectively. The MMP11 expression status was further correlated with clinicopathological features as well as disease-specific survival (DSS) and metastasis-free survival (MeFS). Univariate and multivariate statistical analyses were performed to evaluate the prognostic predictors. Findings: MMP11 protein overexpression was significantly associated with advanced pT status (upper urinary tract, p< 0.001; urinary bladder, p<0.001), nodal metastasis (upper urinary tract, p<0.001; urinary bladder, p=0.012), vascular invasion (upper urinary tract, p<0.001; urinary bladder, p<0.001), and perineural invasion (upper urinary tract, p=0.002; urinary bladder, p=0.006) in both groups of urothelial carcinomas. MMP11 overexpression not only predicted worse DSS (upper urinary tract, p<0.0001; urinary bladder, p<0.0001) and MeFS (upper urinary tract, p<0.0001; urinary bladder, p<0.0001) at univariate analysis, but also inferior DSS (upper urinary tract, p=0.005; urinary bladder, p=0.010) and MeFS (upper urinary tract, p=0.018; urinary bladder, p=0.026) in multivariate analysis. Interpretation: MMP11 overexpression is associated with more aggressive tumour phenotype and poor prognosis for patients with urothelial carcinomas of the upper urinary tract and urinary bladder, suggesting it may serve as a potential prognostic and a novel therapeutic target of urothelial carcinoma. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

44. P0093 AMACR overexpression is associated with clinical and biological aggressiveness in urothelial carcinomas of the upper urinary tract and urinary bladder.

Author

Li, C.-F., Wu, W.-J., Huang, C.-N., Li, C.-C., Ke, H.-L., Li, W.-M., Yeh, H.-C., Lee, Y.-Y., Lin, H.-H., Yeh, B.-W., Hwang, S.-J., and Liang, P.-I.

Subjects
*TUMOR markers, *ACADEMIC medical centers, *CONFERENCES & conventions, *IMMUNOHISTOCHEMISTRY, *MULTIVARIATE analysis, *POLYMERASE chain reaction, *REVERSE transcriptase polymerase chain reaction, *THERAPEUTICS, BLADDER tumors
Abstract

Background: Alpha-methylacyl CoA racemase (AMACR) is essential for catabolism of branched-chain fatty acids, allowing their subsequent β-oxidation to generate energy. However, its significance has not been assessed in urothelial carcinoma. We therefore analysed the clinicopathological and biological significance of AMACR expression in urothelial carcinoma. Methods: Laser capture microdissection coupled with real-time qRT-PCR was used to detect AMACR transcript level in 22 urothelial carcinomas of the urinary bladder. Immunohistochemistry evaluated by using H-score was used to determine AMACR protein expression in 295 urothelial carcinomas of the urinary bladder and 340 urothelial carcinomas of the upper urinary tract. mRNA and protein expression were correlated with clinicopathological features. AMACR protein expression was further evaluated for associations with disease-specific survival (DSS) and metastasis-free survival (MeFS). In vitro, AMACR overexpressing urothelial carcinoma cell lines (BFTC905 and RTCC-1) were evaluated for its biological function using RNA interference. Findings: Increments of AMACR transcript level was associated with higher pT status (p=0.017). AMACR protein overexpression was significantly associated with advanced pT status (both p<0.001), nodal metastasis (both p≼0.001), high histological grade (both p≼0.001), vascular invasion (urothelial carcinomas of the upper urinary tract, p<0.001; urothelial carcinomas of the urinary bladder, p=0.003), frequent mitoses (urothelial carcinomas of the upper urinary tract, p=0.007; urothelial carcinomas of the urinary bladder, p<0.001) in both groups of urothelial carcinomas. AMACR overexpression not only predicted worse DSS and MeFS at univariate analysis, but was also associated with inferior DSS (urothelial carcinomas of the upper urinary tract, p=0.025; urothelial carcinomas of the urinary bladder, p=0.001) and MeFS (urothelial carcinomas of the upper urinary tract, p=0.028; urothelial carcinomas of the urinary bladder, p=0.019) in multivariate analysis. In both urothelial carcinoma cell lines, stable AMACR knockdown resulted in impaired cell proliferation, as well as migration/invasion capabilities. Interpretation: AMACR overexpression is associated with advanced clinical features for patients with urothelial carcinoma and may serve as a potential prognostic biomarker and a novel therapeutic target. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results